Back to search

Article

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort

2022-09-06

Abstract excerpt

Multiple targeted therapeutics have been approved by the FDA for mUC, including immune checkpoint inhibitors (ICIs) and more recently targeted agents for both FGFR and Nectin-4. FGFR3 -aberrant and Nectin-4 expressing cells have been associated with an immunosuppressed phenotype. Given that less than half of all patients respond to these agents as monotherapies, and less than 20% are eligible to receive salvage th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
40e10e98-1006-5a6a-8d9d-ed238d7554c0
DOI
10.21203/rs.3.rs-2014708/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohortDOI 10.21203/rs.3.rs-2014708/v1
Novel molecular biomarkers to guide treatment-decision making in metastatic urothelial cancer - A patient cohort analysisSemantic proximity
Translation of the 27-gene immuno-oncology test (IO Score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patientsSemantic proximity
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.Semantic proximity
T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancerSemantic proximity
Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.Semantic proximity
Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancerSemantic proximity
Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor TypesSemantic proximity
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.Semantic proximity
Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer.Semantic proximity
Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.Semantic proximity
Development and validation of the Immune Profile Score (IPS), a novel multi-omic algorithmic assay for stratifying outcomes in a real-world cohort of advanced solid cancer patients treated with immune checkpoint inhibitorsSemantic proximity
Select a neighboring publication to make it the new centre.